An additional factor that must be considered is that EML4–ALK fusions were detected in only about 5% of lung adenocarcinoma, and it was mutually exclusive to other EGFR mutations and K-ras mutations [43]. The gene discussed is KRAS; the disease is lung adenocarcinoma.